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Abstract 27 
Recent years have seen the emergence into circulation of a growing array of novel psychoactive 28 
substances (NPS). Knowledge of the pharmacological profiles and risk liability of these compounds is 29 
typically very scarce. Development of chemoinformatic tools enabling prediction of properties within 30 
uncharacterised analogues has potential be of particular use. In order to facilitate this, compilation of 31 
a chemical inventory comprising known NPS is a necessity. 32 
Sourcing a variety of published governmental and analytical reports, a dataset composed of 690 33 
distinct acknowledged NPS, complete with defined chemical structures, has been constructed. This is 34 
supplemented by a complementary series of 155 established psychoactive drugs of abuse (EPDA). 35 
Classification was performed in accordance with their key molecular structural features, subjective 36 
effect profiles and pharmacological mechanisms of action. In excess of forty chemical groupings, 37 
spanning seven subjective effect categories and six broad mechanisms of pharmacological action, 38 
were identified. Co-occurrence of NPS and EPDA within specific classes was common, showcasing 39 
inherent scope both for chemical read-across and for the derivation of structural alerts.  40 
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1. Introduction 41 
Over the course of the previous decade, the emergence onto the unregulated market of novel, 42 
predominantly synthetic psychoactive compounds – ƌefeƌƌed to heŶĐefoƌth as ͞Ŷoǀel psyĐhoaĐtiǀe 43 
suďstaŶĐes͟ ;NP“Ϳ – has grown to constitute an increasing public health concern across much of the 44 
developed world.[1] Such agents are typically intended to mimic closely the effects associated with 45 
established, very often illicit, psychotropic drugs of abuse (examples of which are provided within 46 
Figure 1.). Their initial presence outside of the boundaries of substance control schedules within many 47 
legislative areas has led to theiƌ aĐƋuisitioŶ of the populaƌ desĐƌiptoƌ ͞legal highs͟.[2] Whilst numerous 48 
nations have since taken action to bring under control the broad chemical classes within which these 49 
compounds typically fall, emergence of new analogues is continuous. The yet incomplete knowledge 50 
concerning their pharmacological and toxicological profiles ensures therefore that their presence and 51 
use continues to form an ever-evolving and potentially substantial risk towards consumers.[3] 52 
 53 
 54 
Figure 1.Scheme outlining identity and chemical structure of a selection of established psychoactive drugs of 55 
abuse, accompanied by relevant novel analogues. 56 
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NPS may be sourced in practice through an assortment of routes, and in an array of formulations. 57 
͞Head shops͟, pƌeseŶt both as traditional street-side locations and increasingly online, offer a variety 58 
of products either individually or as constituents within mixtures.[4] Sold typically under descriptions 59 
suĐh as ͞ heƌďal iŶĐeŶse͟ oƌ ͞ pot pouƌƌi͟, aŶd fuƌtheƌ ĐoŵŵoŶly ƌefeƌƌed to as ͞ “piĐe͟, ĐaŶŶaďiŵiŵetiĐ 60 
blends composed of a variety of synthetic cannabinoid species are acknowledged as constituting a 61 
significant proportion of this market.[5] Stimulant and empathogenic compounds (distributed 62 
ĐlassiĐally as ͞ďath salts͟ oƌ ͞plaŶt food͟Ϳ additioŶally fiŶd ǁide aǀailaďility, as do psyĐhedeliĐ 63 
tryptamines and lysergamides, opioid agonists and sedatives.[6] Commonly sold as ͞ƌeseaƌĐh 64 
ĐheŵiĐals͟, theiƌ uŶƌegulated souƌĐiŶg aŶd pƌoduĐtioŶ allied to the undefined nature of many 65 
formulations contributes to the uncertainty which surrounds identification of single NPS. The 66 
discerning of pharmacological and toxicological properties attributable to them is therefore rendered 67 
a demanding and non-trivial task.[7] Challenge is additionally posed to the analytical chemist, who must 68 
define routes towards the characterisation of an ever-expanding library of structures.[8] 69 
Attempts to understand in greater depth the impacts upon physical and mental wellbeing associated 70 
with the abuse of specific NPS are confounded by a variety of factors. These derive both from the 71 
inherent novelty of the compounds, and from the unregulated, often clandestine nature of their 72 
production and distribution. Owing to the rapid and continuing emergence of novel substances, there 73 
exists in general a paucity of reliable experimental and clinical data concerning their toxicological 74 
potential. Case studies acquired from patients who have presented following acute ingestion of a 75 
cocktail of NPS –  either in the presence or absence of established illicit psychoactive drugs –  76 
constitute the dominant testimony apparent within the literature.[9-12] Such reports display obvious 77 
limitations with regards to the characterisation of individual compounds, most notably with regards 78 
to specific cellular and organ-level toxicities and dependency profiles over extended periods of use. 79 
Although it is noted that both in vivo and in vitro experimental data are largely non-existent for the 80 
great majority of compounds which have emerged over the preceding 10-15 years, appreciation of 81 
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relevant structure-activity relationships may allow for the inference of the capacity of a substance to 82 
react towards given adverse outcomes. As such, there exists significant scope for the input of 83 
chemoinformatic and predictive toxicological approaches within characterisation of the properties 84 
possessed by this diverse range of chemical subtypes. Pooling of related molecules into relevant 85 
groups further has the capacity to assist in predicting pharmacology, drawing upon similarity with 86 
established drugs whilst simultaneously permitting extrapolation to novel substances as their 87 
presence becomes known. 88 
The essential first step towards any chemoinformatic consideration of NPS is in the curation of a 89 
compound inventory, complete with defined, unambiguous structure relating each constituent 90 
molecule. A variety of national and supra-national government and advisory agencies have, over the 91 
preceding ten years, issued periodical lists of named compounds considered by their experts to fall 92 
within the bracket of NPS. It is from these, complemented by a variety of independent analytical 93 
sources, that we have sought to construct an expansive compendium of NPS acknowledged as 94 
constituting wider concern. As such, the aim of this study was to compile and categorise known NPS 95 
and provide basis for comparison – both structurally and mechanistically – with established 96 
psychoactive compounds. Presented is a dataset composed of 690 novel psychoactive substances, 97 
classified according to their purported effect profiles, neuropharmacological mode of action and 98 
structural composition. Comparison was made with an accessory compilation consisting of 155 99 
established psychoactive drugs of abuse, generally possessive of recognised pharmacological and 100 
toxicological profiles.  101 
 102 
 103 
 104 
 105 
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2. Materials and methods 106 
 107 
2.1. Compilation of database 108 
 109 
Two distinct datasets, one composed solely of recorded NPS and another consisting of established 110 
psychoactive drugs of abuse (EPDA), were developed in accordance with protocols described below. 111 
In instances whereby compounds were found to occupy both classifications, placement preferentially 112 
within the latter grouping was ensured. Each may be found located in its entirety within 113 
Supplementary Table 1. 114 
 115 
Novel psychoactive substances 116 
 117 
Information concerning the identities of compounds acknowledged as NPS was accumulated from 118 
sources as outlined within Table 1. Amongst the literature drawn upon were reports issued through 119 
governmental and supra-governmental entities including the United Nations Office on Drugs and 120 
Crime (UNODC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 121 
alongside a selection of original research publications and reviews developed by independent groups. 122 
A comprehensive index of source material, incorporating assignment of origin for each substance, is 123 
present within Supplementary Table 1. 124 
Established psychoactive drugs of abuse 125 
Substances constituting ͞illiĐit͟ grouping within the DrugBank resource (www.drugbank.ca) were 126 
examined for their purported psychoactive properties.[13[ Those adjudged as possessing no such 127 
liability (primarily steroidal compounds utilised for physical effect) were removed from consideration, 128 
furnishing a 155-member established psychoactive drug of abuse set.  129 
 130 
 131 
 132 
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Reference Entries Reference Entries 
UNODC, 2013[14] 234 Debruyne & Le Boisselier, 2015[28] 122 
EMCDDA, 2006[15] 12 Banister et al., 2015[29] 12 
EMCDDA, 2007[16] 6 Banister et al., 2016[30] 18 
EMCDDA, 2008[17] 14 Qian et al., 2017[31] 9 
EMCDDA, 2009[18] 12 Shevyrin et al., 2014[32] 3 
EMCDDA, 2010[19] 24 Shevyrin et al., 2016[33] 1 
EMCDDA, 2011[20] 39 Uchiyama, Matsuda et al., 2014[34] 13 
EMCDDA, 2012[21] 46 Uchiyama, Shimokawa et al., 2014[35] 8 
EMCDDA, 2013[22] 73 Uchiyama et al., 2015[36] 11 
EMCDDA, 2014[23] 74 Nakajima et al., 2015[37] 4 
EMCDDA, 2015[24] 94 Blakey et al., 2016[38] 8 
EMCDDA, 2016[25] 101 Lai et al., 2015[39] 6 
EMCDDA, 2017[26] 60 Coppola & Mondola, 2012[40] 5 
NFL Slovenia[27] 77   
 133 
Table 1. Summary of literature sources from which NPS identities were drawn.  134 
 135 
2.2. Acquisition and visualisation of chemical structures 136 
In instances where not provided explicitly within source publications, molecular structures 137 
corresponding to listed compounds were obtained through online resources including PubChem 138 
(www.pubchem.gov), ChemSpider (www.chemspider.com) and the New Synthetic Drugs Database 139 
(http://www.nsddb.eu/).[41, 42] Details concerning structural composition were coded for each entry as 140 
SMILES strings.[43] Visualisation was achieved subsequently through use of ChemAxon MarvinView 141 
software (version 1.6).[44] 142 
 143 
2.3. Grouping and classification of compounds 144 
 145 
Grouping with respect to psychoactive effect 146 
Classification as regards psychotropic influence was performed with reference to descriptions present 147 
within source literature. Ancillary information, as required, was obtained through use of the Erowid 148 
online resource (www.erowid.org).[45] 149 
 150 
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Grouping with respect to pharmacological mechanism of action 151 
Assorted literature sources, referenced in the text, were employed in order to attribute the dominant 152 
neuropharmacological mechanism to constituent compounds. 153 
 154 
Grouping with respect to molecular structural features 155 
Molecules were visualised in accordance with protocols described above. Chemical and 156 
pharmacological knowledge was employed in order constitute groups related by shared, biologically-157 
relevant stƌuĐtuƌal ŵotifs. Those falliŶg outside of suĐh Đategoƌies ǁeƌe teƌŵed ͞uŶĐlassified͟. 158 
 159 
2.4. Principal component analysis of chemical space 160 
Descriptors relating to the physicochemical and structural properties of compounds contained within 161 
NPS and EPDA sets were determined through use of CORINA Symphony Descriptors Community 162 
Edition (v. 2, MN-AM, Nuremberg, Germany: www.mn-am.com/services/corinasymphonydescriptors). 163 
Further series of parameters, centred upon the presence within structures of definitive chemical 164 
fingerprints, were developed through assistance of the ChemoTyper application (v. 1.1, MN-AM, 165 
Nuremberg, Germany) with reference to established ToxPrint chemotypes.[46] Physicochemical and 166 
structural descriptors (in total 31, refer to Supplementary Table 3 for their identity) were integrated 167 
into combined arrays, from which principal components were extracted using Principal Component 168 
Analysis within the Minitab Statistical software (v. 18.1, State College PA, USA).  Visualisation, in the 169 
form of scatter plots, was achieved through use of this same program.  170 
 171 
 172 
 173 
 174 
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3. Results 175 
3.1. Overview and analysis of dataset 176 
A total of 690 compounds characterised as NPS were identified from within the aforementioned 177 
sources. With regards to purported psychoactive properties (as displayed visually within Figure 2), 223 178 
were distinguished as cannabinoids, 192 as stimulants, 118 as psychedelics, 63 as empathogens, 39 as 179 
sedatives, 25 as opioids, and 20 as dissociatives. Owing to insufficient attestation coupled with 180 
structural obscurity, 10 compounds, labelled ͞ uŶĐeƌtaiŶ͟, had no definitive effect or effects attributed. 181 
367 of these compounds influenced monoaminergic transmission, 223 cannabinergic, 36 GABAergic, 182 
25 opioidergic, 19 glutamatergic and 6 cholinergic (with 14 uncertain). Substances were further 183 
partitioned, where appropriate, into one of 35 distinct chemical groupings. A selection of 43 isolated 184 
ĐoŵpouŶds defied suĐh ĐategoƌisatioŶ, aŶd ǁeƌe iŶ tuƌŶ listed ͞uŶĐlassified͟. From the Drugbank 185 
͞Illicit͟ dataset, a sum of 155 psychoactive compounds was gathered. In all, 70 could be identified as 186 
opioids, 40 as sedatives, 21 as stimulants, 15 as psychedelics, 4 as dissociatives, 4 as empathogens and 187 
1 as cannabinoid. These entries spanned 23 distinct chemical classifications, incorporating six absent 188 
amongst NPS.                    189 
                      190 
Figure 2. Numerical composition of psychoactive effect groups. 191 
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Principal component analysis of physicochemical and structural properties was performed upon the 192 
NPS dataset. Outcomes are expressed visually within plots (Figure 3), detailing comparison of scores 193 
obtained between principal components 1 and 2. Evident within Figure 3A, the dominant groupings 194 
of cannabinergic and monoaminergic agents are seen to occupy areas of chemical space largely 195 
distinct from one-another. Grouping according to psychoactive effect (Figure 3B) illustrates extent of 196 
overlap between monoamine-like stimulant, empathogen and psychedelic agents. 197 
 198 
 199 
Figure 3. Principal component analyses of NPS dataset. Scores relating first principal components, with 200 
compounds grouped In accordance with their pharmacological mechanism of action (A) and psychoactive effect 201 
profile (B). 202 
 203 
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Substance inventories may be viewed in their entirety through accessing of Supplementary Data. 204 
Supplementary Table 1 incorporates the sum of relevant data concerning compound nomenclature, 205 
structure and classification. For summary of chemical and psychoactive effect classification overlap, 206 
Supplementary Table 2 should be consulted.  207 
 208 
3.2. Consideration of psychoactive categories 209 
 210 
3.2.1. Monoaminergic 211 
 212 
Pathways of dopaminergic, adrenergic and serotonergic transmission hold integral roles within 213 
regulation of cognition, perception and emotion. Perturbation in the functioning of these systems 214 
relates closely, dependent upon mechanistic specificity, to a range of psychoactive influences 215 
extending from therapeutic alleviation of depression to induction of intense psychedelic and 216 
hallucinogenic experience. There are in practice numerous physiological processes associated with 217 
neurotransmitter regulation as modulated through the actions of neuroactive substances, and as such 218 
the pharmacology of such compounds is varied. Whilst receptor agonism and antagonism is a feature 219 
within selected classes, enhancement of synaptic neurotransmitter concentration through induction 220 
of release or inhibition of reuptake forms a generally dominant mode of action.[47, 48] 221 
In the overwhelming majority of instances, a close chemical similarity to endogenous 222 
neurotransmitters is apparent (as highlighted within Figure 4). Functionalisation of the 223 
phenylethylamine unit central within catecholamines dopamine (DA) and NA permits rational design 224 
of compounds possessive of a spectrum of stimulant, empathogenic and psychedelic effects. 225 
Tryptamine-derived serotonin (5-HT) mimics, as direct 5-HT receptor agonists, are further notable for 226 
their hallucinogenic influence.  227 
 228 
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 229 
Figure 4. Overview of shared structural motifs common to endogenous neurotransmitters and monoaminergic 230 
NPS.  231 
 232 
3.2.1.1 Stimulant 233 
Characterised by a capacity to invoke senses of wakefulness and heightened energy, the typical 234 
stimulant belongs to the broad family of substituted phenylethylamines (as outlined within Table 2). 235 
Cathinone and pyrrolidinophenone derivatives are notably numerous, forming as they do common 236 
constitueŶts ǁithiŶ ͞ďath salt͟ ďleŶds.[6] Tropane cocaine analogues and modafinil mimics form 237 
notable categories based upon alternative structural motifs. 238 
 Structural basis NPS EPDA 
Aminoindane  
2-AI, 5-IAI,  
NM-2-AI 
None 
Varying patterns of DA, NA and 5-HT reuptake inhibition and release.[49] 
Conformationally-restricted phenylethylamine.  
Empathogen (1), stimulant (2) 
13 
 
Amphetamine 
 
Methiopopamine, 
DMA, 4-MA 
(Total 21) 
Amphetamine, 
cathine, 
methamphetamine 
(Total 5) 
Stimulation of DA release, inhibition DA, NA and 5-HT reuptake.[50] 
Empathogen (7), psychedelic (2), stimulant (12) 
Arylpiperazine  
BZP, MBZP,  
4-MeOPP 
(Total 17) 
None 
Varying patterns of DA, NA and 5-HT reuptake inhibition and release.[51, 52] 
Stimulant (17) 
Benzylpiperidine  
Ethylphenidate,  
propylphenidate 
pipradrol 
 (Total 15) 
None 
Stimulation of DA, NA release with concurrent inhibition of reuptake.[48, 51, 53] 
Conformationally-restricted phenylethylamine. 
Stimulant (15) 
Cathinone 
 
Ethcathinone, 
buphedrone, 
hexedrone 
(Total 61) 
Cathinone, 
diethylpropion 
Stimulation of DA release, inhibition DA, NA and 5-HT reuptake.[54, 55] 
Empathogen (8), psychedelic (1), stimulant (52) 
Modafinil-like 
 
Modafinil, 
adrafinil, 
fladrafinil 
(Total 5) 
None 
Purported perturbation of DA transmission.[56] 
Stimulant (5) 
Phenylalkylamine 
- other  
Phenethylamine, 
NMPEA, 
camfetamine  
(Total 15) 
Chlorphentermine, 
oxilofrine, 
sibutramine 
(Total 5) 
Generally possessive of stimulant activity. 
Incorporating phenibut, a GABAergic sedative. 
Sedative (1), stimulant (14) 
Phenylmorpholine 
 
Phenetrazine, 
isophenmetrazine, 
G-130  
(Total 12) 
Phenmetrazine, 
phendimetrazine 
Stimulation of DA, NA release.[57] 
Conformationally-restricted phenylethylamine. 
Stimulant (12) 
14 
 
Pyrrolidinophenone 
 
α-PVP, 
4'-Fluoro-α-PVP, 
α-PNP 
(Total 44) 
None 
Stimulation of DA release, inhibition DA, NA and 5-HT reuptake.[58]  
Stimulant (44) 
Tropane and 
analogues  
Dichloropane, 
nitracaine, 
dimethocaine 
(Total 8) 
Cocaine, ecgonine, 
benzoylecgonine 
Inhibition of DA, NA and 5-HT reuptake.[48,59]  
Hyoscine and hysocamine alternatively function as cholinergic deliriants.   
Stimulant (6), psychedelic (2) 
Minor 
Methoxyphenylalkylamine – other (4), 
non-specified alkaloid (4),  
unclassified (5) 
4-EA NBOMe,  
2-MA, vanoxerine 
(Total 13) 
Amineptine, 
aminorex, pemoline 
(Total 4) 
 239 
Table 2. Overview of key structural features, prominent category entries and recovered EPDA analogues related 240 
to chemical groupings prevalent amongst stimulant NPS. 241 
 242 
3.2.1.2. Empathogen 243 
Such compounds are characterised by their broad similarity in psychoactive effect to 244 
methylenedioxymethamphetamine (MDMA) – described commonly as the induction of stimulation 245 
and euphoria accompanied by heightened feelings of social connectivity.[59, 60] Their distinctive 246 
properties are associated with increased serotonergic potency, likely a function of the fused 247 
tryptamine-like heterocyclic units apparent in benzofurans and methylenedioxyphenylalkylamines 248 
(detailed in Table 3).  249 
 Structural basis NPS EPDA 
Benzofuran 
 
 
5-APB, 6-APB,  
5-EAPB 
(Total 15) 
 
None 
Inhibition of reuptake and stimulation of release of DA, NA and 5-HT. Agonism at 5-
HT2 receptor.[60]  
Empathogen (14), psychedelic (1) 
Methylenedioxy- 
phenylalkylamine  
Ethylone, 
butylone, EDMA 
(Total 29) 
 
MDMA, MMDA,  
tenamfetamine 
(Total 4) 
 
Inhibition of reuptake and stimulation of release of DA, NA and 5-HT. Weak agonism 
at 5-HT2 receptor.[54, 61]  
Empathogen (27), psychedelic (2) 
15 
 
 
Oxazoline 
  
3,4-DMAR, 
4,4'-DMAR,  
N-Methyl 
aminorex 
derivative 
Aminorex, 
4-methylaminorex, 
pemoline 
Inhibition of DA, NA and 5-HT reuptake, alongside stimulation of 5-HT release.[62] 
Bears conformationally-restricted phenylethylamine moiety. 
Empathogen (3) 
Minor 
Aminoindane (1), amphetamine (7), 
cathinone (8), 
methoxyphenylalkylamine – other (2), 
tryptamine (1) 
Mephedrone,  
4-FA, 5-API 
(Total 19) 
None 
 250 
Table 3. Overview of key structural features, prominent category entries and recovered EPDA analogues related 251 
to chemical groupings prevalent amongst empathogen NPS. 252 
 253 
 254 
3.2.1.3. Psychedelic 255 
NP“ appeaƌiŶg uŶdeƌ the desĐƌiptioŶ ͞psyĐhedeliĐ͟ are noted for their induction of altered states of 256 
perception characterised by visual hallucination and profound changes in cognition. As direct agonists 257 
at selected 5-HT receptors (refer to Table 4), tryptamine serotonin analogues and dimethoxy-258 
substituted phenylalkylamines constitute the bulk of this class.[63, 64] 259 
 260 
 Structural basis NPS EPDA 
xC-
Phenylalkylamine 
 
 
2C-C, 2C-I, 2C-N 
(Total 23) 
 
 
2C-B, 2C-T-7 
 
Agonism and antagonism across 5-HT2 receptors.[65] 
Dimethoxy substituent essential in induction of hallucinogenic effect.[66] 
Psychedelic (23) 
xC-NBx-
Phenylalkylamine 
 
25B-NBOMe 
25C-NBOMe 
25N-NBOMe 
(Total 21) 
None 
Agonism at 5-HT2 receptors.[67] 
Dimethoxy substituent essential in induction of hallucinogenic effect. 
Psychedelic (21) 
16 
 
DOx amphetamine 
 
DOC, DOI, 
DOB-Dragonfly 
(Total 9) 
DOET, DOB, DOM 
(Total 4) 
Agonism across 5-HT2 receptors.[68] 
Dimethoxy substituent essential in induction of hallucinogenic effect.  
Psychedelic (9) 
Lysergamide 
 
LSA, AL-LAD,  
ETH-LAD 
(Total 7) 
LSD 
Agonism across broad range of 5-HT receptors.[64, 69]  
Tryptamine unit embedded within polycyclic framework. 
Psychedelic (7) 
Methoxy-
phenylalkylamine 
- other  
Mescaline,  
proscaline, 3C-E 
(Total 18) 
3,4,5-Trimethoxy- 
amphetamine,  
4-Methoxy- 
amphetamine 
Psychedelic effect generally present with dialkoxy and trialkoxy substitution. 
Monomethoxy associated with stimulant profile. 
Psychedelic (12), stimulant (4), empathogen (2) 
Tryptamine 
 
DPT, α-TMT, 
MET  
(Total 34) 
α-MT, DMT, 
bufotenine 
(Total 6) 
Agonism across 5-HT1 and 5-HT2 receptors.[63, 70, 71]  
Structural analogue of serotonin.  
Empathogen (1), psychedelic (32), sedative (1) 
Quinoline alklaloid 
 
Nuciferine, 
aporphine, 
glaucine 
None 
Pattern of activity unestablished. DA receptor agonism noted.[72] 
Psychedelic (3) 
Minor 
Amphetamine (2), benzofuran (1), 
cathinone (1), methylenedioxy-
phenylalkylamine (2), tropane and 
analogues (2), unclassified (3) 
Hyoscamine, 
 5-MeO-DiBF, 
5-MAPDI 
(Total 11) 
None 
 261 
Table 4. Overview of key structural features, prominent category entries and recovered EPDA analogues related 262 
to chemical groupings prevalent amongst psychedelic NPS. 263 
 264 
 265 
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3.2.2. Cannabinergic 266 
Cannabinoid 267 
A variety of synthetic agonists active at cannabinoid CB1 and CB2 receptors have, through consequence 268 
of the populaƌity of ͞“piĐe͟-style blends, entered into circulation.[73] With exception of the notable 269 
class of THC-like cyclohexylphenols, the great majority of developed compounds display structures – 270 
typically carbonyl-substituted indole and indazole derivatives – distinct from natural endogenous or 271 
phytochemical activators (listed in full within Table 5).  272 
 273 
 Structural basis NPS EPDA 
Cyclohexylphenol 
 
HU-210, HU-308 
CP-47,497 
(Total 10) 
THC 
Agonist at CB receptors.[73] 
Structural analogues of THC. 
Indole-alkyl 
carboxamide 
 
ADBICA, STS-135, 
MN-25 
(Total 57) 
 
None 
 
Agonist at CB receptors. 
Indole-alkyl ketone 
 
UR-144, AB-001, 
AM-1248 
 (Total 14) 
None 
Agonist at CB receptors. 
Indole-aryl 
carboxamide 
 
SGT-25, MN-24, 
PX-1 
 (Total 28) 
None 
Agonist at CB receptors. 
Indole-naphthyl 
ketone 
 
JWH-018, JWH-200, 
AM-2201 
 (Total 55) 
None 
Agonist at CB receptors. 
18 
 
Indole-phenyl 
ketone 
 
RCS-4, JWH-250, 
AM-679 
 (Total 31) 
None 
Agonist at CB receptors. 
Incorporating benzoylindoles and phenylcacetylindoles. 
Indole-quinoline 
ester 
 
PB-22, NM-2201,  
BB-22 
(Total 12) 
None 
Agonist at CB receptors. 
Minor 
Unclassified (16) Methanandamide, 
JWH-175, URB597 
None 
 274 
Table 5. Overview of key structural features, prominent category entries and recovered EPDA analogues related 275 
to selected chemical groupings prevalent amongst cannabinoid NPS. 276 
 277 
3.2.3. GABAergic 278 
Sedative 279 
Exclusively inhibitory in effect, potentiation of signalling through GABA receptors imparts sedative 280 
and depressant outcome. GABAergic drug classes, including benzodiazepines and quinazolines, 281 
function in general as allosteric receptor agonists, occupying distinct binding sites.[74] Kavalactones –  282 
a selection of natural products isolated from the roots of kava (Piper methysticum) – exert effects 283 
through an apparently distinct mechanism.[75] Further covered, exclusively under the heading of 284 
EPDA (and hence omitted from inclusion within Table 6), is the barbiturate class.  285 
 Structural basis NPS EPDA 
Benzodiazepine 
 
 
Etizolam, 
nitrazolam, 
phenazepam 
(Total 21) 
 
Diazepam, 
midazolam, 
prazepam 
(Total 20) 
Allosteric agonism of GABAA receptor.[76] 
Sedative (21) 
Kavalactone 
 
Kavain, methysticin, 
yangonin   
(Total 6) 
None 
Potentiation of GABA signalling through undefined mechanism.[77, 78]. 
Sedative (6) 
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Quinazoline  
 
Etaqualone, 
afloqualone, 
mebroqualone 
 (Total 4) 
Methaqualone 
Allosteric agonism of GABAA receptor.[79] 
Sedative (4) 
Minor 
Non-specified alkaloid (1), 
phenylalkylamine – other (1), 
tryptamine (1), unclassified (5) 
5-HTP, 
1,4-butanediol, 
zopiclone 
(Total 8) 
Pregabalin, 
fospropofol, GHB 
(Total 9) 
 286 
Table 6. Overview of key structural features, prominent category entries and recovered EPDA analogues related 287 
to chemical groupings prevalent amongst sedative NPS. 288 
 289 
 290 
3.2.4. Glutamatergic  291 
 292 
Dissociative 293 
 294 
Whilst three primary classes of excitatory ionotropic glutamate receptor are characterised, it is those 295 
of the NMDA variety which are considered of greatest pharmacological relevance. Antagonists, 296 
notably analogues of ketamine and phencyclidine (PCP), are associated with unique forms of 297 
dissociative anaesthesia – incorporating states typiĐally ĐhaƌaĐteƌised ďy halluĐiŶatioŶ, ͞out-of-ďody͟ 298 
experience and sedation.[80, 81] Table 7 details the prominent chemical groupings. 299 
 Structural basis NPS EPDA 
Aryl- 
cyclohexylamine 
 
Methoxetamine, 
deschloroketamine, 
4-MeO-PCP 
(Total 14) 
 
PCP, PCPy, 
tenocyclidine, 
(Total 4) 
Non-competitive antagonism at NMDA receptor.[82] 
Dissociative (14) 
Diarylethylamine 
 
Ephenidine, 
diphenidine, 
NPDPA 
(Total 5) 
None 
Non-competitive antagonism at NMDA receptor.[83] 
Incorporates opioidergic MT-45.  
Dissociative (4), opioid (1) 
Minor 
Unclassified (2) Salvinorin A, 
memantine 
None 
 300 
Table 7. Overview of key structural features, prominent category entries and recovered EPDA analogues related 301 
to chemical groupings prevalent amongst dissociative NPS. 302 
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3.2.5. Opioidergic 303 
Opioid 304 
 305 
AgoŶists at the ŵajoƌ suďĐlasses of opioid ƌeĐeptoƌ ;δ, κ, μ aŶd ŶoĐiĐeptiŶͿ aƌe Đapaďle of iŶduĐiŶg 306 
potent analgaesic effect, coupled commonly with mild euphoria.[84] Dependence liability is notably 307 
high.[85] A variety of categories, including the numerous analogues of morphine, methadone and 308 
pethidine (excluded from Table 8) occur exclusively as EPDA.  309 
 Structural basis NPS EPDA 
Dichlorobenzamide 
 
AH-7921, 
U-47700, U-49900 
None 
Agonism across range of opioid receptor subtypes.[86] 
Opioid (3) 
Fentanyl derivative 
 
Acetylfentanyl, 
valerylfentanyl, 
furanylfentanyl 
(Total 16) 
Fentanyl, 
carfentanil, 
lofentanil 
(Total 22) 
Agonism across range of opioid receptor subtypes.[87] 
Opioid (16) 
Minor 
Diarylethylamine (1),  
non-specified alklaloid (3), unclassified 
(2) 
W-15, 
mitragynine, 
akuammine 
(Total 6) 
None 
 310 
Table 8. Overview of key structural features, prominent category entries and recovered EPDA analogues related 311 
to chemical groupings prevalent amongst opioid NPS. 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
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4. Discussion 322 
 323 
The recent emergence into circulation of an expanding library of novel psychoactive substances (NPS) 324 
constitutes an evolving risk to public health. Efforts to define the landscape of identified compounds 325 
with respect to their effect profiles and structural features have proved challenging on account both 326 
of the novelty and obscurity of many, and further of the generally narrow scope of reports attesting 327 
their detection and characterisation. As such, the intentions of this study have been to collate from 328 
accessible source material an expansive inventory of definitively-acknowledged NPS. Like entries were 329 
classified with respect to chemical, pharmacological and psychoactive similarity and, where 330 
appropriate, related to analogous established drugs of abuse. 331 
In total, a sum of 690 distinct novel substances were identified, supplemented by 155 established 332 
drugs of abuse. It is apparent that, considered broadly, composition in terms of psychoactive profile 333 
amongst the NPS set exhibits significant variation from that noted across EPDA (refer to Section 3.1.). 334 
This is illustrated starkly in the preponderance of synthetic cannabinoids present within the former 335 
(matching solely in effect against THC), and additionally by the comparative dominance of opioids – 336 
notably the exclusive classes of morphine, methadone and pethidine analogues – amongst the latter. 337 
Whilst the development and spread of cannabimimetics represents a recent phenomenon, the 338 
establishment over many decades of opiate-like substances within clinical practice has contributed 339 
towards the characterisation of their liability towards abuse and in turn to their scheduling.[88] 340 
There remains a substantial number of chemical categories co-occurring within both novel and 341 
established sets. Contributing substantially towards impetus behind the development of NPS has been 342 
the desire to circumvent existing legislation concerning control of well-characterised recreational or 343 
abuse-liable drugs.[9] As such, the synthesis of structural analogues through minor modification of 344 
known compounds with an intention of retaining or even potentiating desired psychoactive outcome 345 
has assisted greatly in spurring the upturn in emergence of new substances (notably amongst the 346 
readily-adapted monoaminergic phenylalkylamines). Analogues of amphetamine and cathinone are 347 
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accordingly plentiful, whilst similarly well-represented are methylenedioxy entries mimicking 348 
configuration of MDMA and hallucinogenic methoxy-substituted 2C- and DOx equivalents.[63, 89] 349 
Despite the general obscurity of a great number of these newer molecules, aspects of their 350 
psychoactive and toxicological profiles be inferred with confidence through application of the more 351 
extensive knowledge accrued within their established relatives – methodology akin to that of ͞ƌead-352 
aĐƌoss͟.[90-92] Such a principle which can similarly be extended to function within all chemically-related 353 
categories incorporating at least a single EPDA analogue and across which pharmacological 354 
mechanism of action can be reliably postulated as shared. This is a list which may include, but would 355 
not be limited to, the serotonergic tryptamines and lysergamides, glutaminergic arylcyclohexylamines, 356 
GABAergic benzodiazepines and opioid fentanyl analogues. 357 
In contrast to the aforementioned structural mimics, which correspond closely to recognised 358 
psychoactive substances, a variety of classes exhibit novelty and distinctness in molecular composition. 359 
In such instances the breadth and quality of study data relating the properties of member compounds 360 
is typically inferior, and cross-group extrapolation of effects a more substantial challenge. 361 
Consideration of attributed pharmacological mechanism of action, alongside governing structure-362 
activity relationships, adopts greater importance. A variety of notable categories fall under this broad 363 
description, including benzofuran phenylalkylamines, diaryethylamines and the great majority of 364 
synthetic cannabinoids. Uncharacterised benzofurans might reliably be inferred to possess 365 
empathogenic qualities as a function of their structural similarity to the methylenedioxy MDMA 366 
derivatives, implying a monoaminergic mode of action (common to phenylalkylamines) distinguished 367 
by further weak serotonin receptor agonism.[61] Diarylethylamines likewise share great 368 
correspondence with NMDA antagonist arylcyclohexylamines – a class of dissociatives including 369 
amongst its number the extensively-studied ketamine and PCP.  370 
The single largest effect category present within NPS, definitive characterisation of synthetic 371 
cannabinoid action presents unique challenges. Of the 223 compounds identified, a mere ten (each of 372 
23 
 
the cyclohexylphenol class) bear structural relation to THC. Composing the remainder are an array of 373 
functionalised nitrogen heterocycle derivatives, distinct in composition from established 374 
psychoactives. It therefore follows that whilst the shared mechanism of cannabinergic receptor 375 
agonism ensures predictability in short-term subjective effects, inference of the physical and 376 
psychological consequences of continued use constitutes a greater trial. Ease of functionalisation 377 
ensures that the development of novel analogues remains ongoing, with the composition of 378 
cannabimimetic blends showing great variety.[5] 379 
Examples considered across the above text provide broad overviews of how predictive approaches, 380 
based upon consideration of molecular similarity, might be employed in order to credibly infer the 381 
properties of the multitude of uncharacterised NPS. Drawing and collating from a variety of 382 
authoritative sources, an extensive survey of the chemical landscape is presented. A total of 647 of 383 
the 690 identified substances (94%) may be placed into one of the 35 defined structural groupings – 384 
a practice which greatly orders and simplifies understanding of the set. Of these classes, 17 are seen 385 
to co-occur amongst EPDA – thus granting scope for direct comparison of effect profile. 386 
Pharmacological system of action is attributable within 676 members (98%) – furnishing mechanistic 387 
rationale which will enhance confidence in proposed structure-activity relationships. To the 388 
knowledge of the authors, this represents the most thorough unified structural repository of NPS – in 389 
terms both of numerical composition and of pharmacological consideration – present within the 390 
literature at this time. Provision of unambiguous structural identifiers for each entry, in the form of 391 
SMILES strings, allows further for ready research use. 392 
 393 
 394 
 395 
 396 
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